B. Hillner

发表

Hospital and physician volume or specialization and outcomes in cancer treatment: importance in quality of cancer care.

B. Hillner, T. Smith, C. Desch, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genomics-based prognosis and therapeutic prediction in breast cancer.

S. Jeffrey, P. Lønning, B. Hillner, 2005, Journal of the National Comprehensive Cancer Network : JNCCN.

Ensuring quality cancer care by the use of clinical practice guidelines and critical pathways.

B. Hillner, T. Smith, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer. Estimates using decision analysis while awaiting clinical trial results.

B. Hillner, T. Smith, C. Desch, 1992, JAMA.

The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in premenopausal women.

B. Hillner, T. Smith, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer.

B. Hillner, T. Smith, T. le Chevalier, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma.

B. Hillner, R. Kyle, J. Berenson, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

What a difference a day makes

R. Centor, B. Hillner, Burce E. Hillner, 1987, Journal of General Internal Medicine.

Evaluating Consensus Among Physicians in Medical Knowledge Base Construction

Blackford Middleton, R. Miller, F. Davidoff, 1993, Methods of Information in Medicine.

Growth in the use of PET for six cancer types after coverage by medicare: additive or replacement?

T. Tosteson, B. Hillner, A. Tosteson, 2012, Journal of the American College of Radiology : JACR.

Costs of care associated with non-small-cell lung cancer in a commercially insured cohort.

B. Hillner, T. Smith, C. Desch, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Assessing the cost effectiveness of adjuvant therapies in early breast cancer using a decision analysis model

B. Hillner, C. Desch, Thomas J Smith, 2004, Breast Cancer Research and Treatment.

Economic Issues in Breast Cancer Care

B. Hillner, 1997 .

Improving the Diagnostic Process for Deep Vein Thrombosis in Orthopaedic Outpatients

B. Hillner, D. Riddle, P. Wells, 2005, Clinical orthopaedics and related research.

from the National Oncologic PET Registry F-Fluoride PET in Patients with Known Prostate Cancer : Initial Results 18 Impact of

R. Coleman, Lucy Hanna, B. Hillner, 2014 .

Optimal management of suspected lower-extremity deep vein thrombosis. An evaluation with cost assessment of 24 management strategies.

B E Hillner, B. Hillner, J. Philbrick, 1992, Archives of internal medicine.

Decision-theoretic Refinement Planning

B. Hillner, 1996, Medical decision making : an international journal of the Society for Medical Decision Making.

American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel.

B. Hillner, R. Chlebowski, J. Ingle, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical decisions associated with positron emission tomography in a prospective cohort of patients with suspected or known cancer at one United States center.

B. Hillner, R. Tunuguntla, M. Fratkin, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mastectomy Cost-EffecUve.

B. Hillner, J. Hayman, 1999 .

Is the use of radiation therapy after mastectomy cost-effective?

B. Hillner, J. Hayman, 1999, Seminars in radiation oncology.

What a Difference a Day Makes: A Decision Analysis of Adult Streptococcal Pharyngitis

R. Centor, B. Hillner, 2022 .

Wiser use of dose-dense adjuvant therapy in breast cancer.

Thomas J. Smith, B. Hillner, 2012, Journal of Clinical Oncology.

Do the large benefits justify the large costs of adjuvant breast cancer trastuzumab?

Thomas J. Smith, B. Hillner, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

American S ociety o f C linical O ncology G uideline o n t he Role o f B isphosphonates i n B reast C ancer

B. Hillner, R. Chlebowski, J. Ingle, 2000 .

Role of perspective and other uncertainties in cost-effectiveness assessments in advanced prostate cancer.

B. Hillner, J. Roberts, 2000, Journal of the National Cancer Institute.

Trade-offs between survival and breast preservation for three initial treatments of ductal carcinoma-in-situ of the breast.

L. Esserman, R. Carlson, B. Hillner, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Methodological and statistical issues of quality of life (QoL) and economic evaluation in cancer clinical trials: report of a workshop.

G. Guyatt, D. Osoba, K. Torfs, 1998, European journal of cancer.

Hospital a nd P hysician V olume o r S pecialization a nd Outcomes i n C ancer T reatment: I mportance i n Q uality o f Cancer C are

Thomas J. Smith, B. Hillner, C. Desch, 2000 .

Differences in initial treatment patterns and outcomes of lung cancer in the elderly.

D. McClish, B. Hillner, T. Smith, 1995, Lung cancer.

Tamoxifen should be cost-effective in reducing breast cancer risk in high-risk women.

B. Hillner, T. Smith, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Lack of Evidence for PET or PET/CT Surveillance of Patients with Treated Lymphoma, Colorectal Cancer, and Head and Neck Cancer: A Systematic Review

B. Hillner, J. Lau, B. Siegel, 2013, The Journal of Nuclear Medicine.

Intended Versus Inferred Treatment After 18F-Fluoride PET Performed for Evaluation of Osseous Metastatic Disease in the National Oncologic PET Registry

Lucy Hanna, B. Hillner, I. Gareen, 2017, The Journal of Nuclear Medicine.

Intended Versus Inferred Management After PET For Cancer Restaging: Analysis of Medicare Claims Linked to a Coverage With Evidence Development Registry

Lucy Hanna, T. Tosteson, B. Hillner, 2013, Medical care.

The National Oncologic PET Registry: expanded medicare coverage for PET under coverage with evidence development.

R. Coleman, B. Hillner, A. Shields, 2007, AJR. American journal of roentgenology.

Impact on Patient Management of [18F]-Fluorodeoxyglucose-Positron Emission Tomography (PET) Used for Cancer Diagnosis: Analysis of Data From the National Oncologic PET Registry.

Lucy Hanna, B. Hillner, A. Shields, 2016, The oncologist.

NCCN Task Force Report : Positron Emission Tomography ( PET ) / Computed Tomography ( CT ) Scanning in Cancer

R. Coleman, R. Advani, A. Zelenetz, 2007 .

JNCCN NCCN Task Force Report : PET / CT Scanning in Cancer

R. Coleman, R. Advani, A. Zelenetz, 2007 .

Physicians as gatekeepers. The impact of financial incentives.

B. Hillner, C. Clancy, 1989, Archives of internal medicine.

Cost-Effective Use of Autologous Bone Marrow Transplantation

Thomas J. Smith, B. Hillner, C. Desch, 1994, PharmacoEconomics (Auckland).

Cost-effectiveness of routine radiation therapy following conservative surgery for early-stage breast cancer.

B. Hillner, J. Hayman, J. Weeks, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trends i n C linical T rials R eports i n C ommon C ancers B etween 1989 a nd 2 000

B. Hillner, 2003 .

18F-Fluoride PET Used for Treatment Monitoring of Systemic Cancer Therapy: Results from the National Oncologic PET Registry

Lucy Hanna, B. Hillner, A. Shields, 2015, The Journal of Nuclear Medicine.

Impact of 18F-Fluoride PET in Patients with Known Prostate Cancer: Initial Results from the National Oncologic PET Registry

R. Coleman, Lucy Hanna, B. Hillner, 2014, The Journal of Nuclear Medicine.

Estimating the cost effectiveness of total androgen blockade with flutamide in M1 prostate cancer.

E D Crawford, B E Hillner, E. Crawford, 1995, Urology.

Role of Decision Analysis in Relation to Clinical Trials and a US Perspective of the Battelle Model

B. Hillner, 2012, PharmacoEconomics.

High-dose chemotherapy with autologous bone marrow transplantation for metastatic breast cancer.

B. Hillner, T. Smith, C. Desch, 1992, JAMA.

Risk for breast cancer declined after postmenopausal hormone therapy was stopped

B. Hillner, 2009, Annals of Internal Medicine.

American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel.

B. Hillner, R. Chlebowski, J. Ingle, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Relationship Between Cancer Type and Impact of PET and PET/CT on Intended Management: Findings of the National Oncologic PET Registry

R. Coleman, B. Hillner, I. Gareen, 2008, Journal of Nuclear Medicine.

A comparison of patterns of care of nonsmall cell lung carcinoma patients in a younger and Medigap commercially insured cohort

B. Hillner, T. Smith, C. Desch, 1998, Cancer.

The Quality of Cancer Care : Does the Literature Support the Rhetoric ? Submitted to the National Cancer Policy board April 9 , 1999

Thomas J. Smith, B. Hillner, 1999 .

Geographic and sociodemographic disparities in PET use by Medicare beneficiaries with cancer.

T. Tosteson, B. Hillner, A. Tosteson, 2012, Journal of the American College of Radiology : JACR.

Cost-effectiveness analysis of three regimens using vinorelbine (Navelbine) for non-small cell lung cancer.

B. Hillner, T. Smith, 1996, Seminars in oncology.

Does a clinical trial warrant an economic analysis?

B. Hillner, T. Smith, 1998, Journal of the National Cancer Institute.

Economic analyses of benefit from interferon-alpha 2B in high-risk melanoma: trade-offs between completeness, simplicity and clarity.

J. Kirkwood, B. Hillner, 1997, European journal of cancer.

Concrete options and ideas for increasing value in oncology care: the view from one trench.

Thomas J. Smith, B. Hillner, 2010, The oncologist.

Use of hematopoietic colony-stimulating factors: the American Society of Clinical Oncology survey. The Health Services Research Committee of the American Society of Clinical Oncology.

M. Somerfield, J. Feinglass, B. Hillner, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry.

Barry A Siegel, Barry A. Siegel, R. Coleman, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hospice Admission and Survival After 18F-Fluoride PET Performed for Evaluation of Osseous Metastatic Disease in the National Oncologic PET Registry

Lucy Hanna, B. Hillner, I. Gareen, 2017, The Journal of Nuclear Medicine.

American S ociety o f C linical O ncology C linical P ractice Guidelines: T he R ole o f B isphosphonates i n Multiple M yeloma

K. Anderson, B. Hillner, R. Kyle, 2002 .

Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis.

B. Hillner, T. Smith, C. Desch, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacoeconomic issues in bisphosphonate treatment of metastatic bone disease.

B. Hillner, 2001, Seminars in oncology.

Cost effectiveness and other assessments of adjuvant therapies for early breast cancer.

B. Hillner, T. Smith, 1995, Oncology.

A way forward on the medically appropriate use of white cell growth factors.

Thomas J. Smith, B. Hillner, 2012, Journal of Clinical Oncology.

Ways to reduce the cost of oncology care without compromising the quality.

B. Hillner, T. Smith, C. Desch, 1994, Cancer investigation.

American society of clinical oncology 2003 update on the role of biophosphonates and bone health issues in women with breast cancer

B. Hillner, R. Chlebowski, J. Ingle, 2004 .

The optimal timing of autologous bone marrow transplantation in Hodgkin's disease patients after a chemotherapy relapse.

B. Hillner, T. Smith, C. Desch, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Update on the Role of Bone-Modifying Agents in Metastatic Breast Cancer

R. Theriault, B. Hillner, W. Barlow, 2011 .

American Society of Clinical Oncology Clinical Practice Guideline Update on the Role of Bone-Modifying Agents in Metastatic Breast Cancer

R. Theriault, B. Hillner, W. Barlow, 2011 .

IMPACT OF AMYLOID PET ON PATIENT MANAGEMENT: EARLY RESULTS FROM THE IDEAS STUDY

M. Carrillo, C. Gatsonis, Lucy Hanna, 2017, Alzheimer's & Dementia.

Comment on pegylated liposomal Doxorubicin plus docetaxel in metastatic breast cancer.

Thomas J. Smith, B. Hillner, 2010, Journal of Clinical Oncology.

Cost-effectiveness assessment of interferon alfa-2b as adjuvant therapy of high-risk resected cutaneous melanoma.

B. Hillner, 1998, European journal of cancer.

Racial and Ethnic Differences in Amyloid PET Positivity in Individuals With Mild Cognitive Impairment or Dementia

Barry A. Siegel, M. Carrillo, Lucy Hanna, 2022, JAMA neurology.

Current practice of temporary vena cava filter insertion: a multicenter registry.

B. Hillner, H. Weiss, E. Strecker, 2000, Journal of vascular and interventional radiology : JVIR.

Overview of economic analysis of Le Chevalier Vinorelbine Study.

B. Hillner, T. Smith, 1998, Oncology.

Two plans for universal health insurance.

R. Centor, B. Hillner, D. Himmelstein, 1989, The New England journal of medicine.

Benefit and projected cost‐effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early‐stage estrogen receptor–positive breast cancer

B. Hillner, 2004, Cancer.

A Quantitative Methodology for Determining the Need for Exposure-Prompted Medical Monitoring

B. Hillner, P. Guzelian, C. Guzelian, 2003 .

Imaging dementia: Evidence for amyloid scanning (IDEAS)—a national study to evaluate the clinical utility of amyloid PET

M. Carrillo, B. Hillner, G. Rabinovici, 2015, Alzheimer's & Dementia.

The impact of positron emission tomography (PET) on expected management during cancer treatment

Barry A. Siegel, R. Coleman, Lucy Hanna, 2009, Cancer.

Reply to C.A. Hudis et al

Thomas J. Smith, B. Hillner, 2012 .

Impact of 18F-FDG PET Used After Initial Treatment of Cancer: Comparison of the National Oncologic PET Registry 2006 and 2009 Cohorts

R. Coleman, Lucy Hanna, B. Hillner, 2012, The Journal of Nuclear Medicine.

The National Oncologic PET Registry (NOPR): Design and Analysis Plan

R. Coleman, Lucy Hanna, B. Hillner, 2007, Journal of Nuclear Medicine.

Economic and cost-effectiveness issues in breast cancer treatment.

B. Hillner, 1996, Seminars in oncology.

Reducing the cost of cancer care: how to bend the curve downward.

Thomas J. Smith, B. Hillner, R. Kelly, 2012, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Cost‐effective models for flutamide for prostate carcinoma patients: Are they helpful to policy makers?

B. Hillner, D. Matchar, D. Mccrory, 1996, Cancer.

Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684.

M. Atkins, J. Kirkwood, B. Hillner, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reply to C.G. Azzoli et al and C. Chouaid et al.

Thomas J. Smith, B. Hillner, R. Kelly, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cost effectiveness of crizotinib for anaplastic lymphoma kinase-positive, non-small-cell lung cancer: who is going to blink at the cost?

Thomas J. Smith, B. Hillner, R. Kelly, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bending the cost curve in cancer care.

Thomas J. Smith, Thomas J Smith, B. Hillner, 2011, The New England journal of medicine.

Diagnosis of lower-extremity deep vein thrombosis in outpatients with musculoskeletal disorders: a national survey study of physical therapists.

B. Hillner, D. Riddle, P. Wells, 2004, Physical therapy.

Efficacy does not necessarily translate to cost effectiveness: a case study in the challenges associated with 21st-century cancer drug pricing.

Thomas J. Smith, B. Hillner, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A sociodemographic and economic comparison of breast reconstruction, mastectomy, and conservative surgery.

B. Hillner, T. Smith, C. Desch, 1999, Surgery.

American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer.

J. V. Von Roenn, R. Theriault, B. Hillner, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Free-riding and the prisoner's dilemma: problems in funding economic analyses of phase III cancer clinical trials.

B. Hillner, T. Smith, S. George, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer.

D. DeMets, B. Hillner, D. Allred, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America.

J. Armitage, J. Fay, J. Klein, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma.

N. Schmitz, B. Hillner, T. Smith, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer.

J. Cauley, B. Hillner, R. Chlebowski, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cost-effectiveness of radiation therapy following conservative surgery for ductal carcinoma in situ of the breast.

B. Hillner, J. Hayman, L. Pierce, 2005, International journal of radiation oncology, biology, physics.

Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model.

B E Hillner, B. Hillner, T. Smith, 1991, The New England journal of medicine.

Association Between Ambient Air Pollution and Amyloid Positron Emission Tomography Positivity in Older Adults With Cognitive Impairment.

M. Carrillo, C. Gatsonis, Lucy Hanna, 2020, JAMA neurology.

Cost‐effectiveness analysis of exemestane compared with megestrol in patients with advanced breast carcinoma

Davide Radice, D. Radice, B. Hillner, 2001, Cancer.

The role of bisphosphonates in metastatic breast cancer.

B. Hillner, 2000, Seminars in radiation oncology.

Executive Summary of the Clinical Practice Guideline Update on the Role of Bone-Modifying Agents in Metastatic Breast Cancer

R. Theriault, B. Hillner, W. Barlow, 2013 .

Barriers to clinical trial enrollment: are state mandates the solution?

B. Hillner, 2004, Journal of the National Cancer Institute.

Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia

M. Carrillo, C. Gatsonis, Lucy Hanna, 2019, JAMA.

Financial costs, benefits, and patient risk preferences in node-negative breast cancer: insights from a decision analysis model.

B. Hillner, 1993, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Factors that determine the treatment for local and regional prostate cancer.

B E Hillner, D. McClish, B. Hillner, 1996, Medical care.

The Costs and Benefits of a Screening Program to Detect Dementia in Older Drivers

B. Hillner, S. Retchin, 1994, Medical decision making : an international journal of the Society for Medical Decision Making.

Trends in clinical trials reports in common cancers between 1989 and 2000.

B. Hillner, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predictors of Medicare costs in elderly beneficiaries with breast, colorectal, lung, or prostate cancer

D. McClish, B. Hillner, T. Smith, 1999, Health care management science.

Cost-effectiveness of adding an electron-beam boost to tangential radiation therapy in patients with negative margins after conservative surgery for early-stage breast cancer.

B. Hillner, J. Hayman, L. Pierce, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A cost effectiveness analysis of calcium and vitamin D supplementation, etidronate, and alendronate in the prevention of vertebral fractures in women treated with glucocorticoids.

B. Hillner, L. Buckley, 2003, The Journal of rheumatology.

Estimating the cost-effectiveness of stereotaxic biopsy for nonpalpable breast abnormalities: a decision analysis model.

L. Fajardo, B. Hillner, H. Bear, 1996, Academic radiology.

Do cancer centers designated by the National Cancer Institute have better surgical outcomes?

Philip P Goodney, J. Birkmeyer, N. Birkmeyer, 2005, Cancer.

Impact of a 21-Gene RT-PCR Assay on Treatment Decisions in Early-Stage Breast Cancer

B. Hillner, 2008 .

Postmenopausal estrogens in prevention of osteoporosis. Benefit virtually without risk if cardiovascular effects are considered.

S G Pauker, B E Hillner, S. Pauker, 1986, The American journal of medicine.

rPOP: Robust PET-only processing of community acquired heterogeneous amyloid-PET data

Robert Koeppe, Renaud La Joie, Gil D. Rabinovici, 2021, NeuroImage.

Is cancer care best at high-volume providers?

B. Hillner, 2001, Current oncology reports.

Impact of 18F-Fluoride PET on Intended Management of Patients with Cancers Other Than Prostate Cancer: Results from the National Oncologic PET Registry

R. Coleman, Lucy Hanna, B. Hillner, 2014, The Journal of Nuclear Medicine.

Intended Versus Inferred Care After PET Performed for Initial Staging in the National Oncologic PET Registry

Lucy Hanna, T. Tosteson, B. Hillner, 2013, The Journal of Nuclear Medicine.

Impact of Dedicated Brain PET on Intended Patient Management in Participants of the National Oncologic PET Registry

R. Coleman, Lucy Hanna, B. Hillner, 2010, Molecular Imaging and Biology.

The Cost of Pain.

Thomas J. Smith, B. Hillner, 2019, JAMA network open.

Taking action on the volume-quality relationship: how long can we hide our heads in the colostomy bag?

Thomas J. Smith, Thomas J Smith, B. Hillner, 2003, Journal of the National Cancer Institute.

Efficacy and cost-effectiveness of cancer treatment: rational allocation of resources based on decision analysis.

B. Hillner, T. Smith, C. Desch, 1993, Journal of the National Cancer Institute.

The Parathyroid as a Target for Radiation Damage

B. Hillner, 2011 .

American S ociety o f C linical O ncology 2 003 U pdate o n t he Role o f B isphosphonates a nd B one H ealth I ssues i n W omen With B reast C ancer

J. Cauley, B. Hillner, R. Chlebowski, 2003 .

American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer.

J. Cauley, B. Hillner, R. Chlebowski, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Explaining Marginal Benefits to Patients, When “Marginal” Means Additional but Not Necessarily Small

Thomas J. Smith, B. Hillner, 2010, Clinical Cancer Research.

Should the elderly receive chemotherapy for node-negative breast cancer? A cost-effectiveness analysis examining total and active life-expectancy outcomes.

B. Hillner, T. Smith, C. Desch, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Caring for older women with breast cancer: can observational research fill the clinical trial gap?

B. Hillner, J. Mandelblatt, 2006, Journal of the National Cancer Institute.

Measuring standards of care for early breast cancer in an insured population.

B. Hillner, T. Smith, C. Desch, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Frequency and Cost of Chemotherapy-Related Serious Adverse Effects in a Population Sample of Women With Breast Cancer

B. Hillner, B. E. Hillner, 2007 .

PET and PET/CT Reports: Observations from the National Oncologic PET Registry

R. Coleman, Lucy Hanna, B. Hillner, 2010, Journal of Nuclear Medicine.

Should women with node-negative breast cancer receive adjuvant chemotherapy? — Insights from a decision analysis model

B. Hillner, Thomas J Smith, 2005, Breast Cancer Research and Treatment.

A model of chemotherapy in node-negative breast cancer.

B. Hillner, T. Smith, 1992, Journal of the National Cancer Institute. Monographs.

Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study: A Coverage with Evidence Development Longitudinal Cohort Study

B. Hillner, G. Rabinovici, B. Siegel, 2015 .

Cost‐effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first‐line therapy for metastatic colorectal carcinoma

D. Sargent, B. Hillner, C. Fuchs, 2005, Cancer.

Review of cost-effectiveness assessments of chemotherapy in adjuvant and advanced breast cancer.

B. Hillner, 1998, Anti-cancer drugs.

Variation in staging and treatment of local and regional breast cancer in the elderly

Thomas J. Smith, B. Hillner, C. Desch, 2005, Breast Cancer Research and Treatment.

Quantitative analysis of 6,150 real‐world amyloid Positron Emission Tomography (PET) scans from the Imaging Dementia–Evidence for Amyloid Scanning (IDEAS) study

Barry A. Siegel, M. Carrillo, Lucy Hanna, 2022, Alzheimer's & Dementia.

Erratum: The impact of Positron Emission Tomography (PET) on expected management during cancer treatment (Cancer (2009) 115 (410-8))

R. Coleman, Lucy Hanna, B. Hillner, 2009 .

Decision analysis: a practical example.

T J Smith, B E Hillner, B. Hillner, 1995, Oncology.

2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel.

J. Armitage, James R. Anderson, M. Somerfield, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A decision analysis study of the value of a liver biopsy in nonalcoholic steatohepatitis

B. Hillner, A. Sanyal, J. Gaidos, 2008, Liver international : official journal of the International Association for the Study of the Liver.

Post hoc economic analysis of temozolomide versus dacarbazine in the treatment of advanced metastatic melanoma.

B. Hillner, M. Middleton, S. Agarwala, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Burden of illness associated with metastatic melanoma

J. Kirkwood, B. Hillner, S. Agarwala, 2001, Cancer.

Hospital volume and patient outcomes in major cancer surgery: a catalyst for quality assessment and concentration of cancer services.

B. Hillner, T. Smith, 1998, JAMA.

Allocating cancer-directed expenditures: tensions between prevention, early detection and treatment is unnecessary.

Thomas J. Smith, B. Hillner, 2011, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

PET and PET/CT Reports: Observations from the National Oncologic PET Registry

R. Coleman, Lucy Hanna, B. Hillner, 2010, Journal of Nuclear Medicine.

You are here : Home » Cost of Health Care , Sounding Board » Bending the Cost Curve in Cancer Care Sounding Board

B. Hillner, 2011 .

Intended Versus Inferred Treatment After 18F-Fluoride PET Performed for Evaluation of Osseous Metastatic Disease in the National Oncologic PET Registry

Lucy Hanna, B. Hillner, I. Gareen, 2017, The Journal of Nuclear Medicine.

Estimating the cost-effectiveness of flutamide in metastatic cancer.

B. Hillner, 1996, Cancer treatment reviews.